Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for induction and maintenance treatment of moderately to severely active ulcerative colitis
NL-OMON55646Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in autoimmune colitis, sponsored by AbbVie Inc. Started Mar 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON55646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55646.